Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma

Nivolumab, a programmed death-1 checkpoint inhibitor, is worldwide available for metastatic renal cell carcinoma (mRCC). Limited data exist on the response to vascular endothelial growth factor receptor-tyrosine kinase inhibitor (TKI) therapy after administration of nivolu­mab. In this case study, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Narukawa, Tsukasa, Hongo, Fumiya, Fujihara, Atsuko, Ueno, Akihisa, Matsugasumi, Toru, Ukimura, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154254/
https://www.ncbi.nlm.nih.gov/pubmed/32308585
http://dx.doi.org/10.1159/000506196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154254/
https://www.ncbi.nlm.nih.gov/pubmed/32308585
http://dx.doi.org/10.1159/000506196

Ejemplares similares